Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

2.860 +0.090 (+3.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aldeyra Therapeu

< Previous 1 2 3 4 5 6 Next >
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc
Via Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
From Aldeyra Therapeutics
Via Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference
From Aldeyra Therapeutics
Via Business Wire
Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Upcoming Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.